Highlights
- •Risk stratification and mitigation tools are important for all disease modifying agents in multiple sclerosis.
- •Selection of disease modifying agents involves an understanding of the risk and benefits of medications.
- •Tailor treatment to disease activity and patient characteristics to ensure an optimal balance of efficacy and safety.
Abstract
The increasing availability of new agents to treat multiple sclerosis poses new challenges
for clinicians who seek therapies that are both safe and effective for their patients.
The introduction of additional effective therapies has been accompanied by the recognition
of serious side effects. The clinician now must weigh both the benefits and risks
of therapies to help patients decide which treatment best fits each patient׳s risk/benefit
profile. An optimal selection of therapies relies on a complete understanding of the
risks of therapies and the factors that may help evaluate and mitigate those risks.
An individualized treatment approach that incorporates patient and disease factors
is needed for each patient. In this review we present risk stratification and mitigation
strategies of disease modifying agents for multiple sclerosis.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.Brain. 2003; 126: 1782-1789
- Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity – I. disease modifying action on adjuvant arthritis of the rat.Int J Immunopharmacol. 1985; 7: 7-18
- Effects of leflunomide on immune responses and models of inflammation.Semin Immunopathol. 1993; 14: 381-394
Biogen Idec. Tysabri (natalizumab) injection: full prescribing information; March 2011.
Biogen Idec. Medical information web site. 〈https://medinfo.biogenidec.com/〉; updated 2013. [accessed 07.12.13].
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy.N Engl J Med. 2012; 366: 1870-1880
- A pilot trial of cop 1 in exacerbating-remitting multiple sclerosis.N Engl J Med. 1987; 317: 408-414
- Anti-john cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.Ann Neurol. 2011; 70: 742-750
- Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.N Engl J Med. 2008; 359: 1786-1801
- Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.Mult Scler. 2013;
- Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.Clin Neuropharmacol. 2010; 33: 91-101
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.Lancet Neurol. 2010; 9: 438-446
ClinicalTrials.gov. A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE).
Cohen J. Long-term safety of fingolimod in relapsing multiple sclerosis: update to integrated analyses of phase 2 and 3 studies and extension phases. In: Proceedings of the 28th congress of the European committee for treatment and research in multiple sclerosis; October 12, 2012.
- Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.N Engl J Med. 2010; 362: 402-415
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.Lancet. 2012; 380: 1819-1828
- Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial.Neurology. 2012; 78: 1069-1078
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.Lancet. 2012; 380: 1829-1839
- Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 2 and 3 studies (P843).Mult Scler. 2010; 16: S295
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.Lancet. 2009; 374: 1503-1511
- Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.Mult Scler. 2012; 18: 1278-1289
- Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.Neurology. 2011; 77: 573-579
- Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.Eur J Immunol. 2005; 35: 3332-3342
- Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.Neurology. 2002; 58: S3-S9
- Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate.Eur J Immunol. 1996; 26: 2067-2074
- PML in a patient treated with fumaric acid.N Engl J Med. 2013; 368: 1657-1658
FDA. Gilenya (fingolimod): drug safety communication – safety review of a reported death after the first dose.
FDA. Fingolimod drug label; 2010.
FDA. FDA drug safety communication: new risk factor for progressive multifocal leukoencephalopathy (PML) associated with tysabri (natalizumab); 2012a.
FDA. FDA drug safety communication: revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug gilenya (fingolimod); 2012b.
FDA. Tecfidera FDA approved labeling; 2013a.
FDA. Peripheral and central nervous system drugs advisory committee meeting: Alemtuzumab (BLA 103948\5139) background package; November 13, 2013b.
FDA. FDA drug safety communication: FDA investigating rare brain infection in patient taking gilenya (fingolimod); 2013c. Available from: 〈http://www.fda.gov/Drugs/DrugSafety/ucm366529.htm〉.
- Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.Brain. 2008; 131: 808-817
- Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.Mult Scler. 2010; 16: 342-350
- Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.N Engl J Med. 2012; 367: 1087-1097
- Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.Drug Saf. 2003; 26: 815-827
- Effect of campath-1H antibody on human hematopoietic progenitors in vitro.Blood. 1993; 82: 807-812
- The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study.Eur J Neurol. 2005; 12: 649-656
- Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.N Engl J Med. 2012; 367: 1098-1107
- Anti-JC virus antibodies: Implications for PML risk stratification.Ann Neurol. 2010; 68: 295-303
- Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.Biochem Pharmacol. 1995; 50: 861-867
- Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.Br J Dermatol. 2003; 149: 363-369
- Assessing changes in relapse rates in multiple sclerosis.Mult.Scler. 2010; 16: 1414-1421
- Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.N Engl J Med. 2000; 343: 898-904
- Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.Neurology. 2001; 57: S16-S24
- IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (campath-1H).J Clin Investig. 2009; 119: 2052-2061
- A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N Engl J Med. 2010; 362: 387-401
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.Ann Neurol. 2013; 73: 705-713
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.Neurology. 2009; 72: 402-409
- Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.N Engl J Med. 2005; 353: 369-374
- Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletion.J Leukoc Biol. 2004; 76: 950-960
- Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.N Engl J Med. 2005; 353: 375-381
- Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis.Ann Neurol. 1999; 46: 197-206
- Sudden unexpected death on fingolimod.Mult Scler. 2012; 18: 1507-1508
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.Brain. 2011; 134: 678-692
- Effect of relapses on development of residual deficit in multiple sclerosis.Neurology. 2003; 61: 1528-1532
- Randomized study combining interferon and glatiramer acetate in multiple sclerosis.Ann Neurol. 2013; 73: 327-340
- Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from TOWER, a second, pivotal, phase 3 placebo-controlled study.Neurology. 2013; 80
- MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.Neurology. 2007; 68: 1390-1401
- Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.Arch Neurol. 1999; 56: 1263-1265
Novartis. Novartis statement: Gilenya (fingolimod) safety information update; 2012.
Novartis. Gilenya world watch. 〈http://gilenya-world-watch.com/English.html〉; updated 2013 [accessed 07.12.13].
- 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.Lancet Neurol. 2009; 8: 889-897
- Randomized trial of oral teriflunomide for relapsing multiple sclerosis.N Engl J Med. 2011; 365: 1293-1303
- An update of teriflunomide for treatment of multiple sclerosis.J Ther Clin Risk Manag. 2013; 9: 177-190
- Interferon beta-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial.Mult Scler. 2001; 7: 243-248
- Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial.Neurology. 1993; 43: 662-667
- JCV antibody index stratifies PML risk in natalizumab-treated MS patients.Consort Mult Scler Centers. 2013; DX51
- A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N Engl J Med. 2006; 354: 899-910
- PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS.Neurology. 2001; 56: 1628-1636
- Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.Lancet. 1998; 352: 1498-1504
- Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.Arch Neurol. 2012; 69: 1259-1269
- Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.Curr Med Res Opin. 2012; 28: 767-780
- Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.N Engl J Med. 2006; 354: 911-923
- Black holes in multiple sclerosis: definition, evolution, and clinical correlations.Acta Neurol Scand. 2010; 122: 1-8
Sheikh S., Nestorov I., Russell H., et al. Safety, tolerability, and pharmacokinetics of BG-12 administered with and without aspirin: key findings from a randomized, double-blind, placebo-controlled trial in healthy volunteers (P04.136). Neurology. 2012;78(Meeting Abstracts 1):P04.136.
- Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.Neurology. 2011; 77: 1684-1690
- Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990–2010 based on a meta-analysis and individual case data.PLoS One. 2012; 7: e50347
- Manufacturer׳s response to case reports of PML.N Engl J Med. 2013; 368: 1659-1661
- Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.Eur J Immunol. 1971; 1: 242-248
- Liver injury associated with the beta-interferons for MS: a comparison between the three products.Neurology. 2004; 62: 628-631
- Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial..Neurology. 1993; 43: 655-661
- PML in a patient treated with dimethyl fumarate from a compounding pharmacy.N Engl J Med. 2013; 368: 1658-1659
- Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn׳s disease.N Engl J Med. 2005; 353: 362-368
- Depression and multiple sclerosis: review of a lethal combination.J Rehab Res Dev. 2006; 43: 45-62
- Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.Nature. 1992; 356: 63-66
- A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.J Neurol Neurosurg Psychiatry. 2001; 70: 773-780
Article info
Publication history
Published online: May 19, 2014
Accepted:
May 9,
2014
Received in revised form:
May 8,
2014
Received:
January 24,
2014
Identification
Copyright
© 2014 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
